Compare Oatly Group AB - ADR (OTLY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Spyre Therapeutics Inc. Common Stock — how do they compare? Oatly Group AB - ADR trades at $11.1 (market cap $347.84M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 21.6× Oatly Group AB - ADR's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OTLY | SYRE | |
|---|---|---|
Market Cap | $347.84M | $7.52B |
Volume | 116,933 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $108.92 |
52-Week Low | $8.03 | $22.18 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $852.26M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
